[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368030-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368030-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-ovarian-neoplasms-subtypes-and-therapeutic-options","Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options","","Ovarian cancer arises with marked heterogeneity across histopathological and molecular landscapes, and many underlying mechanisms remain incompletely defined. This review synthesizes recent genetic alteration insights and connects them to therapeutic strategies driven by molecular biomarkers and tumor microenvironment biology. A focused literature search emphasizes genomic changes, biomarker-guided treatments, and modulation of the tumor microenvironment, particularly lipid mediator pathways. The work highlights recurrent alterations such as TP53, MYC, PIK3CA, and KRAS in epithelial and germ cell tumors, and links non-epithelial subtypes to ARID1A and SMARCA4 mutations. It further proposes lipid mediator targets to strengthen immune surveillance via STING-associated innate immune signaling, especially in relapsed disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-ovarian-neoplasms-subtypes-and-therapeutic-options/368030/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-ovarian-neoplasms-subtypes-and-therapeutic-options/368030.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the review on ovarian neoplasms?","Question",{"text":63,"@type":64},"To summarize recent advances in genetic alterations underlying ovarian neoplasms and to explore therapeutic strategies informed by molecular biomarkers and tumor microenvironment factors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which genetic alterations are repeatedly observed across certain ovarian tumor types?",{"text":68,"@type":64},"Recurrent alterations in TP53, MYC, PIK3CA, and KRAS are consistently observed across epithelial and germ cell ovarian tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"How do lipid mediators relate to potential therapies and immune regulation in this review?",{"text":72,"@type":64},"Lipid metabolism is linked to immune surveillance through STING signaling in innate immune cells, suggesting lipid mediators and related genes may be promising therapeutic targets, particularly for relapsed ovarian cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368030,1790274442,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nTargeting Ovarian Neoplasms: Subtypes and Therapeutic Options  \nSeon Young Hong 1, Ahyoung Cho 2, Chang-Suk Chae 1,2, * and Hye Jin You 1,2, *  \nAcademic Editor: Stefano Cianci  \nReceived: 4 November 2025  \nRevised: 2 December 2025  \nAccepted: 14 December 2025  \nPublished: 18 December 2025  \nCitation: Hong, S.Y.; Cho, A.; Chae, C.-S.; You, H.J. Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options. Medicina 2025, 61, 2246 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)medicina61122246  \nCopyright: © 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Republic of Korea; [97199@ncc.re.kr](97199@ncc.re.kr)  \n2 Cancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea  \n* Correspondence: [csc2022@ncc.re.kr](csc2022@ncc.re.kr) (C.-S.C.); [hjyou@ncc.re.kr](hjyou@ncc.re.kr) (H.J.Y.)  \nAbstract  \nThe ovary, as the primary organ responsible for reproduction and new life, plays a central role in female development, maturation, and health. Neoplasms arising from the ovary and its associated tissues exhibit substantial heterogeneity in their histopathological and molecular profiles, many of which remain poorly understood. This review aims to summarize recent advances in the understanding of genetic alterations underlying ovarian neoplasms and to explore therapeutic strategies informed by molecular biomarkers and tumor microenvironmental factors. A comprehensive literature search was performed, focusing on genomic alterations, biomarker-guided therapies, and tumor microenvironmental modulation in ovarian cancers. Emphasis was placed on studies addressing lipid mediator pathways and their roles in immune regulation and therapeutic response. Based on diagnostic classifications, recurrent alterations in TP53, MYC, PIK3CA, and KRAS are consistently observed across epithelial and germ cell ovarian tumors, whereas non-epithelial subtypes such as sex cord–stromal tumors (SCSTs) and small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), are predominantly associated with ARID1A and SMARCA4 mutations, respectively. These findings highlight distinct pathogenic mechanisms linked to specific genetic alterations and reveal potential therapeutic vulnerabilities. Moreover, lipid metabolism has been closely implicated in immune surveillance through STING signaling cascades within innate immune cells, suggesting that lipid mediators and their associated genes may represent promising therapeutic targets in ovarian cancers (OCs) . Targeting lipid mediators could be particularly effective in relapsed OCs, as modulating innate immune cells within the tumor microenvironment (TME) may enhance immune surveillance and improve antitumor responses. Integrating genetic and microenvironmental insights offers a promising direction for developing more effective and personalized therapeutic strategies in OC.  \nKeywords: ovarian cancer; genetic alteration; tumor microenvironment; lipid mediators  \n1. Introduction  \nAccording to recent statistics, 55% of ovarian cancer (OC) patients in the United States are diagnosed with distant metastasis, resulting in a 5-year survival rate of only 31.8%[1] . Similarly, in South Korea, 44.5% of OC patients present with distant metastasis, with a corresponding 5-year survival rate of 44.4%[2,3] . In contrast, patients diagnosed with localized (~90%) or regional (~80%) OC have significantly higher survival rate","cbCaijYdIhoPlVGF","https://ap.wps.com/l/cbCaijYdIhoPlVGF","pdf",842899,23,"English","# Abstract\n# 1. Introduction\n# 2. OC—Histological Subtypes and Genetic Alterations\n## 2.1. OC—Histological Subtypes","[{\"question\":\"What is the main objective of the review on ovarian neoplasms?\",\"answer\":\"To summarize recent advances in genetic alterations underlying ovarian neoplasms and to explore therapeutic strategies informed by molecular biomarkers and tumor microenvironment factors.\"},{\"question\":\"Which genetic alterations are repeatedly observed across certain ovarian tumor types?\",\"answer\":\"Recurrent alterations in TP53, MYC, PIK3CA, and KRAS are consistently observed across epithelial and germ cell ovarian tumors.\"},{\"question\":\"How do lipid mediators relate to potential therapies and immune regulation in this review?\",\"answer\":\"Lipid metabolism is linked to immune surveillance through STING signaling in innate immune cells, suggesting lipid mediators and related genes may be promising therapeutic targets, particularly for relapsed ovarian cancers.\"}]","Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options | PDF",1790174458,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90db4906d9b029b8005b3eebbe869383.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f6b0ed83c42a9b37c20169da4fbf756.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d3d9ff2396d6f3aabcfc3e9c910c4ed.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffe3ea02f6c8fd0e38694337006f8874.webp",980,1385]